Subchondroplasty Procedure in Patients With Bone Marrow Lesions

Bone Marrow Edema Clinical Trial

Official title:

Prospective Post-Market Data Collection on Patients With Bone Marrow Lesions (BMLs) in the Knee Treated With the Subchondroplasty® (SCP®) Procedure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03430219
• Other study ID #: SCP-EMEA-01
• Status: Completed
• Start date: March 1, 2018
• Est. completion date: March 16, 2023

Study information

• Verified date: June 2023
• Source: Zimmer Biomet
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, multi-center, post-market data collection study intended to collect data on the short- and long-term safety and performance of the SCP Procedure.

Description:

Patients with symptomatic BML(s) of the knee(s) who qualify for a SCP Procedure will be invited to participate. This study will enroll up to 95 patients across 4 investigative centers in Europe over a period of 12 months. The maximum study duration is expected to be 6 years.

Follow-up assessments will be conducted at 1 month, 3, 6, 12-months and 24-months post injection; and subjects will be asked questions regarding their pain and functioning to further understand long-term outcomes.

For all subjects at selected centers, a long standing X-ray and MRI at screening and either at 12 months or 24 months will be obtained.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: March 16, 2023
• Est. primary completion date: March 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age at time of screening

• Patient with BML(s) in one or both knees, as diagnosed by the treating physician, willing and eligible to undergo the SCP Procedure

• One or more BML(s) of the tibial plateau and/or femoral condyle extending to the articular surface of the joint confirmed on T2 weighted fat-suppressed or fat-suppressed Proton Density MR Imaging by presence of white signal

• Patient's index knee alignment, which is defined radiographically, must be one of the following: Neutral, 6 degree mechanical varus, or 6 degree mechanical valgus

• Patient is refractory to conservative non-surgical management of BML:

• Having failed 2 or more of the following: hyaluronic acid (HA) injection, corticosteroid injection, non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, bracing, or minimal surgical intervention (e.g. arthroscopy, debridement/chondroplasty, and/or loose body removal)

• and diagnosis of BML is more than 3 months of the study treatment

• Willing and able to comply with the study procedures

• Signed an informed consent form approved by independent ethics committee (IEC)

Exclusion Criteria:

• Existing acute or chronic infections at the surgical site

• Bone in the index knee is non-viable or not capable of supporting and anchoring the implant.

• Known systemic disorders or any systemic inflammatory condition (e.g. rheumatoid arthritis)

• Acute traumatic injuries with open wounds close to the bone defect which are likely to become infected

• Known metabolic bone disease, including disorders in calcium metabolism

• Known immunologic abnormalities, including inflammatory bone disease

• Has a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for 5 years

• Diagnosis of patella-femoral joint OA and/or primarily patella-femoral symptoms

• BML caused by acute trauma less than 3 months prior to enrollment

• Clinical and/or radiographic disease diagnosis of the index knee that includes any of the following:

• Kellgren-Lawrence grade 4 Osteoarthritis (OA)

• BML located at anterior cruciate ligament (ACL)/ posterior cruciate ligament (PCL) insertion

• Any major or cartilage repair or alignment surgery (i.e. osteotomy, autograft, scaffold, marrow stimulation, debridement, all cell-based therapies, etc.) of the index knee within 12 months prior to enrollment

• Pregnant at time of injection

• Lactating at time of injection

• Use of any investigational drug or device within 30 days prior to enrollment

• Use of any investigational biologics within 30 days prior to enrollment

Related Conditions & MeSH terms

• Bone Marrow Edema
• Bone Marrow Lesions

Intervention

Device:
• Subchondroplasty Procedure
AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure

Locations

Country	Name	City	State
Germany	Universitaetsklinikum Regensburg	Regensburg
Italy	Istituto Clinico Humanitas	Rozzano (MI)
Netherlands	Maastricht UMC	Maastricht
Spain	Hospital Universitari Vall d´Hebron	Barcelona
United Kingdom	Gloucestershire Hospitals NHS	Cheltenham
United Kingdom	Harrogate & District NHS FOUNDATION TRUST	Leeds

Sponsors (1)

Lead Sponsor	Collaborator
Zimmer Biomet

Countries where clinical trial is conducted

Germany,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale	Change in pain following SCP Procedure as measured by the KOOS pain subscale. The KOOS is a validated instrument which measures knee pain and function using five subscales: pain, symptoms, function in daily living, function in sport and recreation, and quality of life. The instrument consists of 42 standardized questions each having 5 point Likert response scale.	12 months
Secondary	Knee Injury and Osteoarthritis Outcome Score (KOOS)	Change in KOOS pain and function subscales and overall scores. The KOOS is a validated instrument which measures knee pain and function using five subscales: pain, symptoms, function in daily living, function in sport and recreation, and quality of life. The instrument consists of 42 standardized questions each having 5 point Likert response scale.	2 year
Secondary	Numerical Rating Scale (NRS) pain scale	Change in pain as measured by NRS pain scale. The NRS is a validated measure of knee pain. The NRS is an 11 point Likert type scale anchored by 0 "no pain" and 10 "worst possible pain". Subjects rate their average pain over the last week	2 year
Secondary	EuroQol-5 Dimensions (EQ-5D)	Change in quality of life as measured by EQ-5D. The EQ-5D is a validated instrument that assesses an individual's current health status and heath related quality of life. The EQ-5D-5L descriptive component assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression over five levels of severity	2 year
Secondary	Heath care utilization Questionnaire	Healthcare utilization for each subject will be recorded via a not validated questionnaire to capture information about any treatments, therapies, specialists, etc. utilized for pain or symptom relief following study treatment and follow-up.	2 year
Secondary	Subject global satisfaction Questionnaire	The subject global satisfaction is concerned with determining patient-related factors such as patients' satisfaction with treatment, and experienced health outcomes. The questionnaire uses a not validated 11 point scale anchored by 0 "totally dissatisfied" and 10 "extremely satisfied".	2 year
Secondary	Occurrence of Re-operations	Occurrence of subjects that require any re-operation on the index knee from initial SCP Procedure.	2 year
Secondary	Time to Re-operations	Time from initial SCP Procedure to any re-operation	2 year
Secondary	Occurrence of Revisions	Occurrence of subjects that require revision on the index knee from initial SCP Procedure.	2 year
Secondary	Time to Revisions	Time from initial SCP Procedure to revisions	2 year
Secondary	X-ray	X-ray evaluation of alignment, joint space narrowing, osteophyte and cyst formation and subchondral sclerosis	12 months
Secondary	MRI BML lesion size	MRI evaluation of Bone Marrow Lesion Size	12 months
Secondary	MRI BML type	MRI evaluation of Bone Marrow Lesion Type	12 months
Secondary	MRI Intraosseous vascularity	MRI evaluation of Intraosseous Vascularity	12 months
Secondary	MRI location of injectate	MRI evaluation of Location of Injectate.	12 months
Secondary	Adverse Events	Occurrence of Adverse Events	2 year